Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...
What do you get when you take 8,192 CH570 MCUs, put them on custom PCBs, and write firmware for this interconnected gaggle of cores? In the case of [bitluni]’s project, you get something that’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results